Tirzepatide: Dual GIP/GLP-1 Agonist Research Peptide Guide (2026)
Last updated
Introduction (research-only scope)
Tirzepatide (LY3298176) is a synthetic 39-amino-acid peptide that activates two receptors, GIP and GLP-1, from a single molecule. It was discovered at Eli Lilly and is the reference dual incretin agonist in metabolic research. This guide summarises the mechanism, what the published clinical literature covers, and how to source and verify research-grade material with third-party purity testing. Tirzepatide is an authorised medicine in several jurisdictions under brand names; the research reagent supplied by Peptra Labs is not that medicinal product, is not a medicine, and is sold strictly for in-vitro laboratory research.
Research use only. The material described here is a laboratory reagent for in-vitro research by qualified professionals. It is not a medicine, supplement, cosmetic ingredient or veterinary product, is not for human or animal use, and nothing on this page is medical advice or a claim of effect in any person.
What is tirzepatide?
Tirzepatide is built on the GIP peptide backbone with modifications that confer balanced activity at the GLP-1 receptor and a C20 fatty diacid side chain that binds albumin and extends its half-life to about five days in humans. Its molecular mass is 4813.45 (CAS 2023788-19-2). It was first described in the peer-reviewed literature in 2018 (Coskun et al., Molecular Metabolism), where the authors characterised its receptor pharmacology and early clinical proof of concept.
How the dual-agonist mechanism works
GIP receptor activation
Glucose-dependent insulinotropic polypeptide is the incretin released from intestinal K cells. Tirzepatide is a full agonist at the GIP receptor, and in receptor pharmacology it is often described as GIP-biased: its potency at GIPR is closer to native GIP than its potency at GLP-1R is to native GLP-1.
GLP-1 receptor activation
At the GLP-1 receptor tirzepatide is a partial-to-full agonist depending on the assay, with signalling that favours cAMP over beta-arrestin recruitment. That bias is one of the mechanistic hypotheses researchers use to explain differences from single GLP-1 agonists.
Why dual over single agonism
The research question tirzepatide answers is whether adding GIP activity to GLP-1 activity changes energy-balance and glucose outcomes. It is the two-receptor point on the spectrum that runs from semaglutide (one receptor) to retatrutide (three); see Retatrutide vs Tirzepatide vs Semaglutide.
What the clinical literature covers
Tirzepatide has one of the largest clinical evidence bases of any peptide in this catalog. The SURMOUNT-1 trial (New England Journal of Medicine, 2022) studied it in adults with obesity; the SURPASS programme studied type 2 diabetes; and SURMOUNT-OSA (New England Journal of Medicine, 2024) studied obstructive sleep apnoea with obesity. Those trials used the pharmaceutical product under medical supervision. They are relevant to a research buyer only as mechanism characterisation: the receptor profile is unusually well described, so laboratory work can be designed against a known pharmacology.
Tirzepatide vs semaglutide vs retatrutide
Semaglutide agonises GLP-1R only; tirzepatide adds GIPR; retatrutide adds the glucagon receptor on top of both. In the laboratory the three form a natural series for receptor-selectivity and energy-balance experiments. Our three-way comparison sets the receptor profiles side by side.
How to verify a tirzepatide research peptide is real and pure
Two tests answer two different questions: mass spectrometry confirms identity (the expected mass of 4813.45), HPLC quantifies purity. Our specification for tirzepatide is at least 98% purity. Check the batch number printed on the vial against the lab reports archive: where a batch has been tested, its report is published there and links to the testing laboratory’s own verification page. If the batch you receive is not yet listed, ask us for its documentation before use; a “typical” certificate is not evidence for a specific vial. What a valid certificate must contain is explained in how to read a peptide certificate of analysis.
Storage and reconstitution specific to tirzepatide
Lyophilised tirzepatide is stable when stored sealed, dry and protected from light at 2 to 8 °C for routine laboratory use, and colder for long-term archiving. Once reconstituted with bacteriostatic water it should be kept refrigerated and used within the window your protocol defines; repeated freeze-thaw cycles degrade peptides with fatty-acid side chains. General practice for all our reagents is in the peptide storage protocol.
Regulatory status (FDA, EMA, WADA)
Tirzepatide is an approved medicine in the United States and the European Union under specific brand names for specific indications, dispensed on prescription. That approval attaches to the pharmaceutical product, not to research-grade material: the reagent supplied here is not that product, carries no marketing authorisation, and is for research use only. It is not named on the WADA Prohibited List; the live list is the binding reference. The wider framework is described in the peptide risk profile.
Why labs choose our tirzepatide
Batch-numbered vials, published reports where a batch has been tested, shipping from an EU warehouse with tracking (no customs inside the EU), and prices shown with VAT included. The product page is here: Tirzepatide 10 mg. For sourcing questions in each country, see the buyer guide Buy Tirzepatide in Europe.
References
- Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018. PubMed 30473097
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024. PubMed 38912654